A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa

  • Kern, Johannes (Primary Chief Investigator (PCI))
  • Fernandez-Penas, Pablo (Chief Investigator (CI))
  • Nicolopoulos, Jenny (Chief Investigator (CI))
  • Wong, Celestine (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date9/12/24 → 9/12/27

Keywords

  • clinical trial
  • hidradenitis suppurativa
  • acne
  • remibrutinib

Clinical Trial Phase

  • Phase III (a & b)